As per Airfinity Ltd., the first results to determine the effectiveness of the COVID-19 vaccine expected to come by mid of September from AstraZeneca Plc. Airfinity Ltd is an analytics company that tracks drug trials. AstraZeneca Plc has earlier said that they will provide 30 million doses of the vaccine to the UK by the end of the month.
Other contenders in the race of the COVID-19 vaccine are US’ Moderna Inc. and the US-German partnership of Pfizer Inc. and BioNTech SE.
The preliminary results are only snapshots taken before the study is completed with just a fraction of the data. The WHO had earlier warned countries not to approve a vaccine in a hurry before analyzing its full benefits and risks.
With the relentless spread of the coronavirus in Europe, India and the US, the preliminary numbers may act as an early indicator.
“The first results should be enough to give us a very good idea of where we’re heading. They are moving faster than one could have anticipated,” Airfinity Chief Executive Officer Rasmus Bech Hansen told Livemint.
Unlike drugs, vaccines are administered on relatively healthy people and so far, each of these experimental vaccines has shown promise in smaller trials designed to flag any serious safety concerns and show whether candidates can spur some response from the immune system. The report said.
To have a certainty of the vaccine’s effectiveness in the actual world, the experiment will require tens of thousands of participants against a few hundred people required in early-stage trials.
As per the Airfinity projection, the drugmakers usually ask for regulatory approval before the arrival of the trial’s final results.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told the Los Angeles Times earlier this week, “Overwhelmingly positive interim results could lead to studies being stopped early and the vaccines being rushed to the public.”
Airfinity’s studies are based on publicly available data on trial enrollment and design, together with infection rates in places where patients are enrolled.
Meanwhile, last month, a COVID-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech company BioNTech induces a “robust” immune response in healthy adults aged 18-55 years, according to an interim report of an early phase clinical trial, published in the journal Nature on Wednesday.
The researchers noted that BNT162b1 is an RNA vaccine that elicits an immune response by mimicking the mRNA molecule used by the novel coronavirus SARS-CoV-2 to build its infectious proteins.